Amgen (AMGN) continues to make significant strides in the biotech industry. The FDA's approval of IMDELLTRA in small cell lung cancer has boosted the company's valuation and can potentially change the game for Amgen. The company saw an increase in new investments, with multiple partners such as Stablepoint Partners LLC, GM Advisory Group LLC, and New York State Common Retirement Fund buying and selling shares. Over the last five years, investors in Amgen have enjoyed a decent return of 76%. Jim Cramer has highlighted the importance of Amgen's cholesterol drug and acknowledged the good data from the company's new drug. Amgen's Q3 earnings and revenues surpassed estimates, leading to a rise in share prices. Moreover, the full-year outlook has been revised after Q3 profit and sales jump, contributing to the stock's momentum. The company is also investing in a significant expansion of its U.S. manufacturing, creating hundreds of new jobs. Lastly, Amgen's strong pipeline of therapies and recent trial wins with Repatha have boosted optimism in the company.
Amgen AMGN News Analytics from Sun, 27 Jul 2025 07:00:00 GMT to Sat, 29 Nov 2025 13:48:34 GMT -
Rating 8
- Information 8
- Rumor 5
